Navigation Links
ACT Genomics Raises $8 Million in its First Private Funding Round
Date:2/13/2015

TAIPEI, Feb. 13, 2015 /PRNewswire/ -- ACT Genomics Co., Ltd., a cancer molecular information service company that aims to transform cancer genomic information into precision diagnosis and personalized treatments, today announced that the company has raised US$ 8 million in the its first private funding round.

Based in Taipei, Taiwan, ACT Genomics has developed comprehensive cancer diagnostic tests, ACTDrug™, ACTOnco™. With the aim to implement next generation sequencing (NGS) and multiplex molecular testing platforms to analyze a variety of clinical specimens (i.e., formalin fixed paraffin-embedded tumor tissue, frozen tissue, circulating tumor cells, and purified DNA), the scientists and medical team can accurately detect tumor genomic alternations in more than 400 cancer-related genes, and transform the information into tailored cancer treatments. With advanced next generation sequencing (NGS) and multiplex molecular testing platform, coupling with proprietary bioinformatics engines for clinical reporting, ACT Genomics is capable of providing accurate genomic data and comprehensive interpretation to address key challenges in cancer treatment - "Precision Medicine".

The funding will support the further investment in ACT Genomics' new portfolio of molecular diagnostic assays that can help physicians to address issues in cancer monitoring as well as the expansion of sales, marketing and medical team, the company said in a statement.

Dr. Hua-Chien Chen, the CEO said, "We are very pleased to have completed our first private funding. The R&D progress we made in the past 6 months has impressed the existing and new investors. The additional capital will allow us to continue building robust molecular assays and innovative bioinformatics engine to integrate genome guided medicine database. In addition, we see a significant market opportunity and unmet medical needs for ACT Genomics' cancer diagnostic tests, this round of capital will allow us to expand our team and ultimately to contribute to improve cancer patients' clinical outcomes."

ACT Genomics Contact:

PJ (Joe) Hsueh, MBA, Chief Operating Officer
Email: pjhsueh@actgenomics.com

Angus Wu, Vice Director, Business Development
Email: anguswu@actgenomics.com


'/>"/>
SOURCE ACT Genomics
Copyright©2015 PR Newswire.
All rights reserved

Related biology news :

1. Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine
2. The Genome Institute at Washington University Receives Irys System from BioNano Genomics to Advance Research for Genome Reference Consortium
3. Genomics Market by Products - [Instruments (NGS platform, Microarray, RT-PCR), Consumables (Genechips, Reagents for DNA Extraction & Purification, Sequencing)], Services (Sequencing & Microarray Services, and Software) - Global Forecast to 2018
4. Tute Genomics Launches MyGene Portal for Genome-guided Medicine
5. From the basics to the cutting edge of molecular biology and genomics in one small book
6. BGI Tech launches human whole exome sequencing service on complete genomics advanced platform
7. Eurofins Genomics and AmpTec close distribution agreement for very long synthetic RNAs
8. Structural Genomics Consortium and CHDI Foundation announce new partnership
9. The first termite genome fills a gap in social inset genomics
10. Charismatic organisms still dominating genomics research
11. Pharmocogenomics has not fulfilled its promise to developing countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2019)... ... January 07, 2019 , ... Concerto HealthAI, a ... precision health in oncology and other key therapeutic areas, and its Chief Executive ... entrepreneurs and executives spanning the entire healthcare landscape, on January 8, 2019, at ...
(Date:1/5/2019)... ... January 04, 2019 , ... Join Bill Fox, Chief ... Life Sciences from MarkLogic – for a live webinar on Wednesday, ... challenges of using real world data for pharmacovigilance, and the implications of current ...
(Date:1/4/2019)... WHITEHOUSE, N.J. (PRWEB) , ... January 03, 2019 ... ... to rapidly adopt 3D cell culture models into their drug discovery research workflows ... these models improve the in vivo relevancy of in vitro studies, they create ...
Breaking Biology News(10 mins):
(Date:1/15/2019)... ... January 15, 2019 , ... With the U.S. Congress designating January as Cervical ... (STD) testing service, today announces tips to help reduce the risk of Cervical Cancer. , ... (HPV). Genital HPV is the #1 most common STD and an STI that ...
(Date:1/10/2019)... ... January 08, 2019 , ... ... innovative spinal implant company, announced today that SAGICO will be represented at ... The annual J.P. Morgan Healthcare Conference is the largest and most informative ...
(Date:1/7/2019)... , ... January 07, 2019 , ... ... clinical trials of its Parkinson's Disease drug candidate, code-named "KM-819." KM-819 is ... Disease. The trial took place in South Korea. , This Phase 1 ...
(Date:1/4/2019)... ... 2019 , ... Calidi Biotherapeutics, Inc., a clinical-stage ... the founding of a scientific and medical advisory board (SMAB). The SMAB will ... the Immuno-Oncology field. The founding members of Calidi Biotherapeutics SMAB include Lisa H. ...
Breaking Biology Technology: